First HS patient dosed! Leadingtac IRAK4 Degrader Expands New Indications
2025-07-09
SHANGHAI & SHAOXING, China – July 9, 2025 – Leadingtac Pharmaceutical Co., Ltd., a clinical-stage biotech company focused on innovative drug discovery for autoimmune diseases and oncology, announced today it has dosed the first patient in its Phase Ic clinical trial of LT-002 for the treatment of moderate-to-severe hidradenitis suppurativa (HS).
Learn More